• AlzeCure Pharma released Q2 results with net sales of SEK 97.33 million, compared with no revenue a year earlier.
• Earnings swung to SEK 80.18 million from a loss of SEK 9.76 million; basic EPS turned positive to SEK 0.7 from -SEK 0.11.
• Operating cash flow widened to an outflow of SEK 19.19 million from SEK 7.98 million, while cash totaled SEK 13.49 million.
• For H1, net sales were SEK 97.33 million; earnings swung to SEK 58.49 million from a loss of SEK 19.89 million.
• Signed out-licensing deals with Eli Lilly and QuantumCell, carrying potential value above USD 3.2 billion excluding royalties; received USD 22 million upfront in August.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AlzeCure Pharma AB published the original content used to generate this news brief on August 26, 2026, and is solely responsible for the information contained therein.